Mary Ann Liebert to launch BioResearch Open Access in March

NewsGuard 100/100 Score

BioResearch Open Access, a new bimonthly peer-reviewed open access journal, will launch in March 2012 by Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com). The Journal will provide a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. Further information is available at http://www.liebertpub.com/biores.

The new Journal is under the leadership of Editor Jane Taylor, PhD, Senior Research Fellow, MRC Centre for Regenerative Medicine, University of Edinburgh, and seasoned journal editors as Section Editors, including James M. Wilson, MD, PhD, Gene Therapy Program, University of Pennsylvania; Antonios G. Mikos, PhD, BioScience Research Collaborative, Rice University, Houston, TX; Peter C. Johnson, MD, President and CEO, Scintellix, LLC, Raleigh, NC; Aubrey D.N.J. de Grey, PhD, SENS Foundation, Cambridge, UK; Alan J. Russell, PhD, Distinguished University Professor & Founding Director, McGowan Institute for Regenerative Medicine, University of Pittsburgh & UPMC; Thomas Hope, PhD, Professor of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Ganes C. Sen, PhD, Department of Molecular Genetics, Cleveland Clinic Foundation, Cleveland, OH ; Bruce A. Sullenger, PhD, Director, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, Graham C. Parker, PhD, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI; Carol Shoshkes Reiss, PhD, Department of Biology Center for Neural Science, New York University, New York, NY; Stephen C. Ekker, PhD, Department of Biochemistry and Molecular Biology, Rochester, MN; John B. West, MD, PhD, University of California, San Diego, La Jolla, CA; David L. Woodland, PhD, Chief Scientific Officer, Keystone Symposia on Molecular and Cellular Biology, Silverthorne, CO; and Stephen Higgs, PhD, FRES, Research Director, Biosecurity Research Institute, Kansas State University, Manhattan, KS.

The Journal will publish basic science and translational research in the form of original research articles, comprehensive review articles, mini-reviews, rapid communications, brief reports, technology reports, hypothesis articles, perspectives, and letters to the editor. All articles in BioResearch Open Access will be published online within 4 weeks of acceptance. Articles will be fully open access and posted on PubMedCentral. All articles submitted through May 15, 2012 will be made open access with no article processing charges. BioResearch Open Access is fully NIH-, HHMI- and Wellcome Trust compliant.

The Journal will be published both in print and online. Full details about the Journal are available at http://www.liebertpub.com/biores.

"BioResearch Open Access will be a fully refereed multidisciplinary journal," says Mary Ann Liebert, president of Mary Ann Liebert, Inc. "Reviewers will be selected by highly authoritative Section Editors and papers will be accepted on the basis of those reviews to ensure the integrity of editorial content and provide the checks and balances that rigorous peer review ensures. It is very gratifying that the scientific community is supportive of this fully open access publication and enthusiastic about participating."

Source: Mary Ann Liebert, Inc./Genetic Engineering News

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses